NCT04203693Completed
Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
Observational Study to Assess the Effectiveness, Safety Profile and Real-life Prescribing and Utilization Patterns of Tildrakizumab (Ilumetri®) in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice. (SAIL)
Source: ClinicalTrials.gov · Last updated 2 Mar 2026
Brief summary (registry, in English)
The observational, non-interventional study will assess the efficacy, safety, prescription and utilization patterns of Tildrakizumab in participants with moderate to severe plaque psoriasis in routine clinical practice.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 331 (actual)
- First submitted
- 10 Dec 2019
- Start date
- 30 Oct 2019
- Primary completion date
- 2 May 2024
- Lead sponsor
- Almirall, S.A.
- Diseases
- Psoriasis
- NCT number
- NCT04203693
What you commit to
- Study type: Observational
- Participants enrolled: 331
- From 30 Oct 2019 to the primary completion date, 2 May 2024
- 41 sites in 6 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Unable to comply with the requirements of the study or who in the opinion of the study physician should not participate in the study.
- Participants meeting any of the exclusion criteria specified in the summary of product characteristics (SmPC) of Ilumetri®.
Who the study is looking for
- Written informed consent form.
- Age \>= 18years.
- Moderate to severe chronic plaque psoriasis diagnosis.
- Participants who have participated in Tildrakizumab (Ilumetri®) clinical trials (Cohort 1) OR participants who, according to the physician's therapeutic decision, should start the treatment with Tildrakizumab (Ilumetri®) (Cohort 2).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (41)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.